Photo from wikipedia
We at Bayer think that Moore’s letter on rivaroxaban is misleading.1 Pharmacokinetic properties are not the sole determinants of the appropriate dosing regimen, and the pharmacodynamic effect of rivaroxaban once… Click to show full abstract
We at Bayer think that Moore’s letter on rivaroxaban is misleading.1 Pharmacokinetic properties are not the sole determinants of the appropriate dosing regimen, and the pharmacodynamic effect of rivaroxaban once daily is evident for the full 24 hours after being taken.2 Furthermore, the efficacy of any intervention can only be demonstrated in large interventional clinical trials. The terminal elimination half …
Keywords:
pharmacokinetic properties;
based pharmacokinetic;
dosing based;
rivaraoxaban dosing
Journal Title: British Medical Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Medical Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!